ROSC - ETF AI Analysis
Top Page
Hartford Multifactor Small Cap ETF (ROSC)
Rating:70Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in the most recent month, indicating positive recent momentum.
Broad Sector Diversification
Holdings are spread across many sectors, including health care, financials, consumer cyclical, technology, and others, which helps reduce the impact of weakness in any single industry.
Multiple Strong Top Holdings
Several of the largest positions, such as BrightSpring Health Services, Phibro Animal Health, and others, have delivered strong year-to-date gains that support the fund’s overall performance.
Negative Factors
High U.S. Concentration
Almost all assets are invested in U.S. companies, offering little geographic diversification if the U.S. market struggles.
Mixed Performance Among Top Holdings
A few key holdings, including Indivior and Harmony Biosciences, have shown weak year-to-date performance, which can drag on returns.
Moderate Expense Ratio
The fund’s expense ratio is not especially low for an ETF, meaning fees take a noticeable, ongoing bite out of investor returns.
ROSC vs. SPDR S&P 500 ETF (SPY)
AUM56.35M
RegionNorth America
Expense Ratio0.34%
Beta0.84
IssuerHartford
Inception DateMar 24, 2015
Dividend Yield1.86%
Asset ClassEquity
Index TrackedHartford Multifactor Small Cap Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,579
30 Day Avg. Volume2,007
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
60.64Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering308
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ROSC Summary
Hartford Multifactor Small Cap ETF (ROSC) tracks the Hartford Multifactor Small Cap Index, focusing on smaller U.S. companies across many industries. It owns a wide mix of stocks, including names like Dillard’s and Catalyst Pharma, with big weights in health care, financials, and consumer-related businesses. Someone might invest in ROSC to tap into the long-term growth potential of small companies while spreading risk across many sectors and stocks. A key risk is that small-cap shares can be more volatile than larger, well-known companies, so the price of this ETF can move up and down sharply.
How much will it cost me?The Hartford Multifactor Small Cap ETF (ROSC) has an expense ratio of 0.34%, which means you’ll pay $3.40 per year for every $1,000 invested. This is slightly higher than average for ETFs because it uses an actively managed multifactor strategy to select stocks, aiming to enhance returns and reduce risk. It’s a good option if you’re looking for a strategic approach to small-cap investing.
What would affect this ETF?The Hartford Multifactor Small Cap ETF (ROSC) could benefit from economic growth and innovation in sectors like Health Care and Technology, which are significant parts of its portfolio. However, it may face challenges from rising interest rates or economic slowdowns, which can disproportionately impact small-cap companies and consumer-focused sectors like Consumer Cyclical. Additionally, changes in U.S. regulations or trade policies could affect the ETF's performance due to its focus on U.S. small-cap stocks.
ROSC Top 10 Holdings
ROSC is leaning heavily into U.S. small-cap health care, with names like Pediatrix Medical Group, Catalyst Pharma, and BrightSpring Health Services doing much of the heavy lifting as their shares have been rising on solid earnings and upbeat guidance. Phibro Animal Health has also been a bright spot, though its balance sheet adds a bit of wobble to the story. On the weaker side, Indivior and Harmony Biosciences have been lagging, acting as a mild brake. Overall, performance is driven by a concentrated cluster of U.S. small-cap health names rather than any single standout stock.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Garrett Motion | 1.37% | $750.62K | $5.75B | 197.14% | 71 Outperform | |
| Catalyst Pharma | 1.19% | $654.37K | $3.82B | 29.74% | 83 Outperform | |
| BrightSpring Health Services, Inc. | 1.15% | $633.47K | $11.36B | 153.01% | 67 Neutral | |
| Indivior | 1.14% | $624.39K | $4.58B | 234.16% | 66 Neutral | |
| Organon | 1.13% | $620.90K | $3.53B | 54.43% | 53 Neutral | |
| National Healthcare | 1.11% | $608.72K | $3.12B | 92.93% | 74 Outperform | |
| Pediatrix Medical Group | 1.06% | $582.99K | $1.85B | 54.26% | 76 Outperform | |
| Frequency Electronics | 1.03% | $566.86K | $586.19M | 208.87% | 76 Outperform | |
| Harmony Biosciences Holdings | 0.94% | $517.16K | $1.82B | -10.66% | 81 Outperform | |
| Perdoceo Education | 0.92% | $505.38K | $2.12B | 9.92% | 72 Outperform |
ROSC Technical Analysis
Positive
―
Price Trends
50.57
Positive
49.98
Positive
47.47
Positive
Market Momentum
0.35
Positive
59.79
Neutral
66.43
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ROSC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 52.21, equal to the 50-day MA of 50.57, and equal to the 200-day MA of 47.47, indicating a bullish trend. The MACD of 0.35 indicates Positive momentum. The RSI at 59.79 is Neutral, neither overbought nor oversold. The STOCH value of 66.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ROSC.
ROSC Peer Comparison
Comparison Results
Performance Comparison
ROSC
Hartford Multifactor Small Cap ETF
52.74
12.54
31.19%
AFSM
First Trust Active Factor Small Cap ETF
―
―
―
BKSE
BNY Mellon US Small Cap Core Equity ETF
―
―
―
STXK
Strive 2000 ETF
―
―
―
SYZ
Lazard US Systematic Small Cap Equity ETF
―
―
―
RUSC
US Small Cap Equity Active ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents